Menu Search
Equities

S2Medical AB (publ)

S21:FRA

S2Medical AB (publ)

Actions
  • Price (EUR)0.0021
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change+36.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year S2Medical AB (publ) grew revenues 49.27% from 4.67m to 6.97m while net income improved from a loss of 29.46m to a smaller loss of 22.71m.
Gross margin89.45%
Net profit margin-17.62%
Operating margin20.76%
Return on assets-5.91%
Return on equity-14.21%
Return on investment-14.21%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at S2Medical AB (publ) fell by 2.21m. Cash Flow from Financing totalled 15.47m or 221.90% of revenues. In addition the company used 16.52m for operations while cash used for investing totalled 1.15m.
Cash flow per share-0.0013
Price/Cash flow per share--
Book value per share0.0273
Tangible book value per share-0.005
More ▼

Balance sheet in SEKView more

S2Medical AB (publ) uses little or no debt in its capital structure.
Current ratio0.6751
Quick ratio0.4329
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.